Gatifloxacin in the Treatment of Recurrent Otitis Media and Otitis Media Treatment Failure in Children

• American Academy of Pediatrics, American Academy of Family Physicians, subcommittee on management of acute otitis media: Diagnosis and management of acute otitis media. Pediatrics113, 1451–1465(2004).
   PubMed Web of Science ®Google Scholar
• Leibovitz E , PiglanskyL, RaizSet al.: Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, non comparative, double tympanocentesis study. Pediatr. Infect. Dis. J.22, 943–949(2003).
   PubMed Web of Science ®Google Scholar
• Pichichero ME : Recurrent and persistent otitis media.Pediatr. Infect. Dis. J.19, 911–916(2000).
   PubMed Web of Science ®Google Scholar
• Faden H : The microbiologic and immunologic basic for recurrent otitis media in children.Eur. J. Pediatr.14, 178–183(1995).
   Google Scholar
• Dellit TH , OwensRC, McGowanJE Jr et al.: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis.44(2), 159–177(2007).
   PubMed Web of Science ®Google Scholar
• Soley C , ArguedasA: Single-dose azithromycin for treatment of children with acute otitis media.Expert Rev. Anti Infect. Ther.3(5), 707–717(2005).
   PubMedGoogle Scholar
• Steele DW , KleinJO, RosnerB: Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study.J. Infect. Dis.160, 83–94(1989).
   PubMed Web of Science ®Google Scholar
• Shireman TI , KelsseyKA: Prescribing patterns and retreatment rates in children with otitis media.Clin. Drug Invest.22, 303–311(2002).
   Web of Science ®Google Scholar
• Block SL , HedrickJ, TylerRD, SmithRA, HarrisonCJ: Microbiology of acute otitis media recently treated with aminopenicillins.Pediatr. Infect. Dis. J.20, 1017–1021(2001).
   PubMed Web of Science ®Google Scholar
• Arguedas A , LoaizaC, PérezAet al.: Microbiology of acute otitis media in Costa Rican children. Pediatr. Infect. Dis. J.17, 680–689(1998).
   PubMed Web of Science ®Google Scholar
• Piglansky L , LeibovitzE, RaizSet al.: Bacteriological and clinical efficacy of high dose of amoxicillin for therapy of acute otitis media in children. Pediatr. Infect. Dis. J.22, 405–413(2003).
   PubMed Web of Science ®Google Scholar
• Dowell SF , MarcyMS, PhillipWR, Gerber MA, Schwartz B: Otitis media – principles of judicious use of antimicrobial agents. Pediatrics101, 165–171(1998).
   Web of Science ®Google Scholar
• Roger G , CharlesP, PangonBet al.: Management of acute otitis media caused by resistant pneumococci in infants. Pediatr. Infect. Dis. J.17, 631–638(1998).
   PubMed Web of Science ®Google Scholar
• Dagan R , LeibovitzE: Bacterial eradication in the treatment of otitis media.Lancet Infect. Dis.2, 593–604(2002).
   PubMed Web of Science ®Google Scholar
• Dagan R , LeibovitzE, GreenbertD, YagupskyP, FlissD, LeibermanA: Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome.Pediatr. Infect. Dis. J.17, 776–782(1998).
   PubMed Web of Science ®Google Scholar
• Asher E , GreenbergD, DaganR, PoratN, LeibovitzE: Failure to eradicate otitis media pathogens after 3–5 days of treatment is associated with higher relapse rate in children with initial improvement/cure. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC, USA (2004) (Abstract G-2096).
   Google Scholar
• Dowell SF , ButlerJC, GiebinkGSet al.: Acute otitis media: management and surveillance in an era of pneumococcal resistant – a report from the drug–resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr. Infect. Dis. J.18, 1–9(1999).
   PubMed Web of Science ®Google Scholar
• Jacobs MR , DaganR, AppelbaumPC, BurchDJ: Prevalence of antimicrobial–resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media.Atimicrob. Agents Chemother.42, 589–595(1998).
   PubMed Web of Science ®Google Scholar
• Sáez-Llorens X , RodríguezA, ArguedasAet al.: Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis median in children. Pediatr. Infect. Dis. J.24, 293–300(2005).
   PubMed Web of Science ®Google Scholar
• Zhanel G , EnnisK, VewrcaigneLet al.: A critical review of the fluoroquinolones: focus on respiratory tract infection. Drugs62, 13–59(2002).
   PubMed Web of Science ®Google Scholar
• Gendrel D , MoulinF: Fluoroquinolones in pediatrics.Paediatr. Drugs3, 365–377(2001).
   PubMedGoogle Scholar
• Mandell LA , PetersonLR, WiseRet al.: The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin. Infect. Dis.35, 721–727(2002).
   PubMed Web of Science ®Google Scholar
• Chalumeau M , TonnelierS, D‘AthisPet al.: Fluoroquinolone safety in pediatric children: a prospective, multicenter, comparative cohort study in France. Pediatrics.111, 714–719(2003).
   Web of Science ®Google Scholar
• Schaad UB : Role of new quinolones in pediatric practice.Pediatr. Infect. Dis. J.11, 1043–1046(1992).
   PubMed Web of Science ®Google Scholar
• Grendrel D , ChalumeauM, MoulinF, RaymondJ: Fluoroquinolones in pediatrics: a risk for the patient or the community?Lancet Infect Dis.3, 537–546(2003).
   PubMed Web of Science ®Google Scholar
• Ito T , KojimaK, KoizumiK, NaganoH, NishinoT: Inhibitory activity on DNA gyrase and intracellular accumulation of quinolones: structure–activity relationship of Q-35 analogs.Biol. Pharm. Bull.17, 927–930(1994).
   PubMed Web of Science ®Google Scholar
• Zhao X , XuC, DomagalaJ, DrlicaK: DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.Proc. Natl Acad. Sci. USA94, 13991–13996(1997).
   PubMed Web of Science ®Google Scholar
• Zhao X , WangJY, XuCet al.: Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob. Agents Chemother.42, 956–958. (1998).
   PubMed Web of Science ®Google Scholar
• Rosen JE , ChenD, PrahaladAK, SprattTE, SchluterG, WilliamsGM: A fluoroquinolone antibiotic with a methoxy group at the 8 position yields reduced generation of 8-oxo-7, 8- dihydro-2‘-deoxyguanosine after ultraviolet-A irradiation.Toxicol. Appl. Pharmacol.145, 381–387(1997).
   PubMed Web of Science ®Google Scholar
• Arguedas A , SherL, LópezEet al.: Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr. Infect. Dis. J.22, 949–956(2003).
   PubMed Web of Science ®Google Scholar
• Caparelli E , ReedM, BradleyJet al.: Pharmacokinetics of gatifloxacin in infants and children. Antimicrob. Agents Chemother.49(3), 1106–1112(2005).
   PubMed Web of Science ®Google Scholar
• Hamed K , ArguedasA, Saez-LlorensXet al.: Microbiology response in recurrent otitis media (ROM) and acute otitis media treatment failure (OMTF) gatifloxacin (GAT) vs. amoxicillin/clavulanate (A/C). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, Illinois, USA (2003).
   Google Scholar
• Lubasch A , KellerI, BornerK, KoeppeP, LodeH: Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.Antimicrob. Agents Chemother.44, 2600–2603(2000).
   PubMed Web of Science ®Google Scholar
• Nakashima M , UematsuT, KosugeKet al.: Single- and multiple-dose pharmacokinetics of AM-155, a new 6-fluoro-8-methoxy quinolone in humans. Antimicrob. Agents Chemother.39, 2635–2640(1995).
   PubMed Web of Science ®Google Scholar
• Shiba K , KusajimaH, MomoK: The effects of aluminum hydroxide, cimetidine, ferrous sulfate, green tea and milk on pharmacokinetics of gatifloxacin in healthy humans.J. Antimicrob. Chemother.44(Suppl. A), 141 (1999).
   PubMedGoogle Scholar
• Baba S . Tissue penetration and clinical efficacy of gatifloxacin, a new oral fluoroquinolone, in otorhinolaryn-gological infections. J. Antimicrob. Chemother.44(Suppl. A), 136 (1999).
   PubMed Web of Science ®Google Scholar
• Pichichero M , ArguedasA, DaganRet al.: Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin. Infect. Dis.41, 470–478(2005).
   PubMed Web of Science ®Google Scholar
• Arguedas A , SierraH, SoleyC: Fluoroquinolones in pediatrics.Current Drug Therapy1, 117–125(2006).
   Google Scholar
• Hampel B , HullmanR, SchmidtH: Ciprofloxacin in pediatrics: world wide clinical experience based on compassionate use safety report.Pediatr. Infect. Dis. J.16, 127–129(1997).
   PubMed Web of Science ®Google Scholar
• Danisovicova A , BrenzinaM, BelanDet al.: Magnetic resonant imaging in children receiving quinolones: no evidence of quinolones induced arthropathy. A multicenter survey. Chemotherapy40, 209–219(1994).
   PubMed Web of Science ®Google Scholar
• Fukuda H , HiramatsuK. Primary targets of fluoroquinolones in S. pneumoniae. Antimoicrob. Agents Chemother.43(2), 410–412(1999).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Antimicrobial agents and related therapy. Fluoroquinolones. In: Red book: Report of the community on infectious diseases (25th Edition). Pickering LK (Ed.). Elk Grove Village, IL, USA, 645–646(2000).
   Google Scholar
• Dagan R : Fluoroquinolones in pediatrics.Drugs49, 92–99(1995).
   PubMedGoogle Scholar
• Schaad UB , abdus Salam M, Aujard Y et al.: Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr. Infect. Dis. J.14, 1–9(1995).
   PubMed Web of Science ®Google Scholar
• Nicodemo AC , MendesCMF, OplustilCP, SintoS: In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin, and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.Braz. Infect. Dis. J.5(2), 50–52(2001).
   PubMedGoogle Scholar
• Sher L , ArguedasA, HussemanMet al.: Randomized, investigator blinded, multicenter comparative study of gatifloxacin versus amoxicillin clavulanate in recurrent otitis media and acute otitis media treatment failure in children. Pediatr. Infect. Dis. J.24, 301–308(2005).
   PubMed Web of Science ®Google Scholar
• Gough A , BarsoumNJ, MitchellL, McGuireEJ, de la Iglesia FA: Juvenil canine drug-induced arthropathy: clinicopathologic studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol. Appl. Pharmacol.51, 177–187(1979).
   PubMed Web of Science ®Google Scholar
• Burkhaldt JE , WalterspielJ, SchaadUB: Quinolone arthropathy in animals versus children.Clin. Infect. Dis.25, 1196–1204(1997).
   PubMed Web of Science ®Google Scholar
• Perry CM , OrmrodD, OnrustSV: Gatifloxacin: a review of its use in the management of bacterial infections.Drugs62, 169–207(2002).
   PubMed Web of Science ®Google Scholar
• Fukuda H , HiramatsuK: Primary targets of fluoroquinolones in Streptococcus pneumoniae.Antimicrob. Agents Chemother.43, 410–412(1999).
   PubMed Web of Science ®Google Scholar
• Stahlmann R , LodeH: Safety overview: toxicity, adverse effects and drug interactions. In: The Quinolones (3rd Edition). Andriole VT (Ed.). Academic Press, San Diego, USA 398–453(2000).
   Google Scholar
• Schaad U : Use of the quinolones in pediatrics. In: The Quinolones (3rd Edition). Andriole VT (Ed.). Academic Press, San Diego, USA 397–453(2000).
   Google Scholar
• Marchand CD : Gatifloxacin therapy for children: an antibiotic still in the ‘back room’.Clin. Infect. Dis.41, 479–480(2005).
   PubMed Web of Science ®Google Scholar
• Echols R , HamedK, ArguedasAet al.: Gatifloxacin therapy for children: turn on the light. Clin. Infect. Dis.41, 1824–1825(2005).
   PubMed Web of Science ®Google Scholar
• Peltron S , HoutH, FinkelsteinJet al.: Emergence of 19 A as Virulent and multidrug resistant pneumococcus in Massachusett following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.26, 468–472(2007).
   PubMed Web of Science ®Google Scholar

Website

• Food and Drug Administration‘s Division of Special Pathogen and Immunologic Drug Products. Summary of Clinical Review of Studies Submitted in Response to a Pediatric Written Request. Applicant: Bayer Corporation, Pharmaceutical Division Drug Name Established: Ciprofloxacin. www.fda.gov/cder/foi/esum/2004/19537_Cipro_BPCA_clinical.pdf
   Google Scholar